Start-Up Previews (4/02)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, The New Wave in Gastroenterology, features profiles of Algenix Inc., IntraPace Inc., MediGus Ltd. and Semorex Inc. Plus these Selected Start-Ups across Health Care: Isogenica Ltd., Opt-e-scrip Inc., Renovis Inc. and Time-Concepts.com LLC.
You may also be interested in...
With the era of medical automation upon us, surgeons are increasingly turning to robots and artificial intelligence for better results in the operating suite. See what Frank Pasquale, professor at Brooklyn Law School and author of the book New Laws of Robotics: Defending Human Expertise in the Age of AI, said about it here.
Cancer drug developers should come to the agency early with a package of clinical trials to support accelerated approval and confirm clinical benefit rather than with plans to sequentially conduct such studies, Oncology Center of Excellence’s Richard Pazdur says; he also suggests closer scrutiny ahead of whether postmarketing trials are being conducted with ‘due diligence.’
Accelerated approval of Tivdak in recurrent or metastatic cervical cancer brings Seagen’s fourth cancer therapy and third antibody-drug conjugate to market. Merck is advancing Keytruda in r/mCC as well.